These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 3275127)
1. Prevention of suppression of alloreactive capacity following intravenous injection of neuraminidase-treated allogeneic cells by co-injection of agents competing for asialoglycoprotein receptor. Suda T; Sano S; Hori S; Azuma T; Tateishi N; Hamaoka T; Fujiwara H Reg Immunol; 1988; 1(1):24-31. PubMed ID: 3275127 [TBL] [Abstract][Full Text] [Related]
2. Abrogation of the capacity of delayed-type hypersensitivity responses to alloantigens by intravenous injection of neuraminidase-treated allogeneic cells. Sano S; Suda T; Qian JH; Sato S; Ikegami R; Hamaoka T; Fujiwara H J Immunol; 1987 Dec; 139(11):3652-9. PubMed ID: 3680947 [TBL] [Abstract][Full Text] [Related]
3. Studies on the induction of tolerance to alloantigens. I. The abrogation of potentials for delayed-type-hypersensitivity response to alloantigens by portal venous inoculation with allogeneic cells. Qian J; Hashimoto T; Fujiwara H; Hamaoka T J Immunol; 1985 Jun; 134(6):3656-61. PubMed ID: 2580893 [TBL] [Abstract][Full Text] [Related]
4. Studies on the induction of tolerance to alloantigens. III. Induction of antibodies directed against alloantigen-specific delayed-type hypersensitivity T cells by a single injection of allogeneic lymphocytes via portal venous route. Sato S; Qian JH; Kokudo S; Ikegami R; Suda T; Hamaoka T; Fujiwara H J Immunol; 1988 Feb; 140(3):717-22. PubMed ID: 2448373 [TBL] [Abstract][Full Text] [Related]
5. Studies on the induction of tolerance to alloantigens. II. The generation of serum factor(s) able to transfer alloantigen-specific tolerance for delayed-type hypersensitivity by portal venous inoculation with allogeneic cells. Fujiwara H; Qian JH; Satoh S; Kokudo S; Ikegami R; Hamaoka T J Immunol; 1986 Apr; 136(8):2763-8. PubMed ID: 2420865 [TBL] [Abstract][Full Text] [Related]
6. Fate of allogeneic or syngeneic cells in intravenous or portal vein injection: possible explanation for the mechanism of tolerance induction by portal vein injection. Zhang Y; Yasumizu R; Sugiura K; Hashimoto F; Amoh Y; Lian Z; Cherry ; Nishio N; Ikehara S Eur J Immunol; 1994 Jul; 24(7):1558-65. PubMed ID: 7913037 [TBL] [Abstract][Full Text] [Related]
7. Depression of the induction of murine delayed-type hypersensitivity responses without prolongation of cardiac allograft survival by intravenous neuraminidase-treated allogeneic lymphocytes. Samlowski WE; Shelby J; Robertson BA; Daynes RA Transplantation; 1989 Mar; 47(3):560-4. PubMed ID: 2646787 [No Abstract] [Full Text] [Related]
8. Possible role of neuraminidase in activated T cells in the recognition of allogeneic Ia. Taira S; Nariuchi H J Immunol; 1988 Jul; 141(2):440-6. PubMed ID: 2968401 [TBL] [Abstract][Full Text] [Related]
9. CD1-dependent natural killer (NK1.1(+)) T cells are required for oral and portal venous tolerance induction. Margenthaler JA; Landeros K; Kataoka M; Flye MW J Surg Res; 2002 May; 104(1):29-35. PubMed ID: 11971674 [TBL] [Abstract][Full Text] [Related]
10. The mechanism of tolerance induction of tumor-specific delayed-type hypersensitivity responses by intravenous inoculation of tumor cells. Sato S; Fukuzawa M; Nakajima H; Ogata M; Kosugi A; Fujiwara H; Hamaoka T Jpn J Cancer Res; 1985 Nov; 76(11):1099-106. PubMed ID: 2935516 [TBL] [Abstract][Full Text] [Related]
11. The antigen-bearing eye and the spleen are indispensable in maintaining anterior chamber-associated immune deviation. Yao YF; Inoue Y; Miyazaki D; Hara Y; Shimomura Y; Tano Y; Ohashi Y Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):534-9. PubMed ID: 9040487 [TBL] [Abstract][Full Text] [Related]
12. Tumor progression in vivo: increased soybean agglutinin lectin binding, N-acetylgalactosamine-specific lectin expression, and liver metastasis potential. Reese MR; Chow DA Cancer Res; 1992 Oct; 52(19):5235-43. PubMed ID: 1394127 [TBL] [Abstract][Full Text] [Related]
13. Influence of 2'-deoxyguanosine upon the development of DTH effector T cells and suppressor T cells in vivo. Bril H; van den Akker TW; Molendijk-Lok BD; Bianchi AT; Benner R J Immunol; 1984 Feb; 132(2):599-604. PubMed ID: 6228591 [TBL] [Abstract][Full Text] [Related]
14. Implication for the CD94/NKG2A-Qa-1 system in the generation and function of ocular-induced splenic CD8+ regulatory T cells. Chattopadhyay S; O'Rourke J; Cone RE Int Immunol; 2008 Apr; 20(4):509-16. PubMed ID: 18359787 [TBL] [Abstract][Full Text] [Related]
15. Antigen presentation by Langerhans cells in vivo: donor-derived Ia+ Langerhans cells are required for induction of delayed-type hypersensitivity but not for cytotoxic T lymphocyte responses to alloantigens. Peeler JS; Niederkorn JY J Immunol; 1986 Jun; 136(12):4362-71. PubMed ID: 3519767 [TBL] [Abstract][Full Text] [Related]
16. Immunogenetic analysis of tolerance induction in anti-alloantigen delayed type hypersensitivity responses by portal venous pre-inoculation with allogeneic cells. Shimizu J; Ogata M; Qian JH; Sato S; Kokudo S; Hamaoka T; Fujiwara H Microbiol Immunol; 1987; 31(4):367-74. PubMed ID: 3475532 [TBL] [Abstract][Full Text] [Related]
17. Delayed-type hypersensitivity to allogeneic mouse epidermal cell antigens. III. Analysis of suppressor cells. Ishii N; Kawaguchi H; Aoki I; Takahashi T; Okuda K; Nakajima H Exp Clin Immunogenet; 1987; 4(1):48-55. PubMed ID: 2978839 [TBL] [Abstract][Full Text] [Related]
18. The regulatory role of sialic acids in the response of class II reactive T cell hybridomas to allogeneic B cells. Taira S; Kakiuchi T; Minami M; Nariuchi H J Immunol; 1986 Oct; 137(8):2448-54. PubMed ID: 3531333 [TBL] [Abstract][Full Text] [Related]
19. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses. Niederkorn JY; Streilein JW J Immunol; 1983 Dec; 131(6):2670-4. PubMed ID: 6196396 [TBL] [Abstract][Full Text] [Related]
20. A new method for tolerance induction: busulfan administration followed by intravenous injection of neuraminidase-treated donor bone marrow. Nagahama T; Sugiura K; Lee S; Morita H; Adachi Y; Kwon AH; Kamiyama Y; Ikehara S Stem Cells; 2001; 19(5):425-35. PubMed ID: 11553851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]